



Symic to Present at the BIO Europe Spring Conference

SAN FRANCISCO, Mar. 29, 2016 – Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Rinko Ghosh, President and Chief Business Officer, will present at the BIO Europe Spring Conference in Stockholm. The presentation will address the potential for new therapies in the area of oncology that target the ECM.

Conference details are as follows:

Date: Tuesday, Apr. 5, 2016

Time: 11:15 a.m. CEST

Location: Room E5 Level 0, Kistamässan Convention Center, Stockholm, Sweden

About Symic

Symic is a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, which are important structural and functional macromolecules native to the ECM, play a critical role in healing following injury and in chronic diseases. Symic's proprietary compounds function like proteoglycans, and have been designed to promote healing and repair in a variety of disease states. Symic has two clinical candidates, one in vascular injury and the other in osteoarthritis. In addition, Symic has several preclinical programs in oncology, fibrosis and CNS disorders.

Symic is based in San Francisco. For additional information, please visit the company's website at <http://www.symic.bio> or follow us on Twitter at www.twitter.com/symicbio and LinkedIn at www.linkedin.com/company/symic-bio/.

###

Media Contacts

David Schull or Lena Evans

Russo Partners, LLC

(212) 845-4271

(212) 845-4262

david.schull@russopartnersllc.com

lena.evans@russopartnersllc.com